Plenary Session:
18. Special Plenary Session
Thursday, October 20, 2011: 5:00 PM-7:00 PM
Room: Grand Ballroom (East-West)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the history of HIV/AIDS research, treatment, and prevention
  • dummarize current methods and recent advancements for identifying and treating HIV/AIDS
  • identify the most promising avenues of research for expanding our understanding of HIV/AIDS and potential future methods of combating it
  • examine and discuss the changes with global preparedness for emerging infections and growing cooperation between public health officials worldwide
  • identify the impact emerging infections have on the global community as well as on individual patients
  • expand knowledge concerning prevention and control strategies for emerging and re-emerging global infections 

Target Audience: Vaccinologists, Scientists, Researchers, Public Health Practitioners, Pharmacists, Nurses, Microbiologists, Lab Personnel, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Hospital Epidemiologists, Hospital Administrators, HIV Clinicians, Health Care Workers, Fellows-in-Training, Epidemiologists, Clinicians, Academicians

Tracks: Global ID, Investigative ID, HIV, Pediatric ID, Adult ID

Moderators:  James Hughes, MD, FIDSA, Emory University and Barbara D. Alexander, MD, FIDSA, Duke University

Presentations:

5:00 PM
87
Society and HIVMA Awards
James Hughes, MD, FIDSA

5:20 PM
88
Society and HIVMA Awards
Kathleen Squires, MD

6:20 PM
90

CME Credits: Maximum of 2.0 hours of Category 1 credit possible

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-100-L01-P

Disclosures:

J. Hughes, None

B. D. Alexander, None

J. Hughes, None

K. Squires, Gilead Sciences, GlaxoSmithKline, Merck, and Tibotec, Tobira: Scientific Advisor, Consulting fee
Gilead Sciences, GlaxoSmithKline, Tibotec, Biocryst, Merck: Research Contractor, Research grant
Clinical Care Options: Scientific Advisor, no financial benefit

M. S. Saag, Merck: Consultant and Scientific Advisor, Consulting fee
Adrea Biosciences: Consultant and Scientific Advisor, Consulting fee
Boehringer: Consultant and Scientific Advisor, Consulting fee
Ingelheim: Consultant and Scientific Advisor, Consulting fee
Bristol-Myers Squibb: Consultant and Scientific Advisor, Consulting fee
Gilead: Consultant and Scientific Advisor, Consulting fee
GSK: Consultant and Scientific Advisor, Consulting fee
Pfizer: Consultant and Scientific Advisor, Consulting fee
Vliv: Consultant and Scientific Advisor, Consulting fee
Tibotec: Consultant and Scientific Advisor, Consulting fee
Vertex: Scientific Advisor, Consulting fee
Monogram Biosciences: Research Contractor, Research support
NIH/NIAID: Grant Investigator, Grant recipient

K. Fukuda, None

See more of: Plenary Session

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.